A new analysis of registry data from Catalonia confirms the strong clinical performance of PALACOS bone cements from Heraeus Medical in knee arthroplasty. Compared to other bone cements, PALACOS products demonstrated lower revision rates – particularly among the antibiotic-loaded variants.
The recent study published in the Journal of Experimental Orthopaedics is based on data from the Catalan Arthroplasty Register and covers a ten-year period (2007–2017). The study focused on implant survival following primary knee arthroplasty. For the first time, PALACOS bone cements were compared in a blinded set up with other individual products and brands, taking into account different viscosities and the presence or absence of included antibiotics (PALACOS with and without gentamicin).
The use of PALACOS bone cements – with and without antibiotics – yielded favourable results in terms of revision rates. The most significant difference was observed in the segment of antibiotic-loaded bone cements. The revision rate for PALACOS R+G states 1.8%, compared to 3.9% for the corresponding competitive products.
For the first time, the study also presented data on the medium-viscose bone cement PALACOS MV+G from Heraeus Medical in knee arthroplasty, which also showed convincing results. Here, the revision rate states 1.1% compared to 3.9% for other antibiotic-loaded bone cements over the ten-year period.
The statistical analysis revealed no significantly increased risk of revision for any of the PALACOS products examined.
The study’s findings highlight the importance of evidence-based decision-making in knee arthroplasty and confirm PALACOS bone cements as a reliable option for long-term implant survival.
A new analysis of registry data from Catalonia confirms the strong clinical performance of PALACOS bone cements from Heraeus Medical in knee arthroplasty. Compared to other bone cements, PALACOS products demonstrated lower revision rates – particularly among the antibiotic-loaded variants.
A new analysis of registry data from Catalonia confirms the strong clinical performance of PALACOS bone cements from Heraeus Medical in knee arthroplasty. Compared to other bone cements, PALACOS products demonstrated lower revision rates – particularly among the antibiotic-loaded variants.
The recent study published in the Journal of Experimental Orthopaedics is based on data from the Catalan Arthroplasty Register and covers a ten-year period (2007–2017). The study focused on implant survival following primary knee arthroplasty. For the first time, PALACOS bone cements were compared in a blinded set up with other individual products and brands, taking into account different viscosities and the presence or absence of included antibiotics (PALACOS with and without gentamicin).
The use of PALACOS bone cements – with and without antibiotics – yielded favourable results in terms of revision rates. The most significant difference was observed in the segment of antibiotic-loaded bone cements. The revision rate for PALACOS R+G states 1.8%, compared to 3.9% for the corresponding competitive products.
For the first time, the study also presented data on the medium-viscose bone cement PALACOS MV+G from Heraeus Medical in knee arthroplasty, which also showed convincing results. Here, the revision rate states 1.1% compared to 3.9% for other antibiotic-loaded bone cements over the ten-year period.
The statistical analysis revealed no significantly increased risk of revision for any of the PALACOS products examined.
The study’s findings highlight the importance of evidence-based decision-making in knee arthroplasty and confirm PALACOS bone cements as a reliable option for long-term implant survival.
Copy to clipboard 
